These results support that 5-aza-2-dC can overcome paclitaxel drug resistance and inhibit tumor growth of paclitaxel-resistant OCCC partly through affecting the HIN-1-AKT-mTOR signaling pathway. Here, MTOR is linked to neoplasm.